Loading...
Metformin is the approved therapy for type 2 diabetes mellitus, but its efficacy in maintaining glycemic control often dissipates with time.
To determine whether adding the glucagon-like peptide-1 analogue liraglutide to metformin can safely improve glycemic control, investigators conducted an industry-funded, international, multicenter, randomized, controlled, phase III trial involving 135 metformin-treated children with type 2 diabetes (aged 10–16 years). Patients received metformin with or without basal insulin plus either subcutaneous liraglutide (escalated to 1.8 mg per day) or placebo.
Results were as follows:
Mean glycated hemoglobin levels at week 26 (the primary endpoint) decreased by 0.64% with liraglutide but increased by 0.42% with…